CPhI: The time of the CMO is up­on us as mas­sive in­dus­try growth dri­ves surge in out­sourc­ing ca­pac­i­ty

Con­tract man­u­fac­tur­ers are hav­ing a mo­ment, and it hasn’t gone un­no­ticed by the folks at CPhI.

The or­ga­ni­za­tion’s an­nu­al re­port found that CMOs will ac­count for four of the five top com­pa­nies by man­u­fac­tur­ing ca­pac­i­ty in 2025. Dawn Eck­er, a CPhI ex­pert, pre­dicts that the bi­o­log­ics man­u­fac­tur­ing vol­ume will grow 8% a year to that dead­line, ex­pand­ing from 2,700kL in 2020 to 3,900kL in 2025.

Near­ly half of all ca­pac­i­ty will shift from in-house man­u­fac­tur­ing to CMOs and hy­brid com­pa­nies, her find­ings re­vealed, and if trends stay con­sis­tent, the big-dog con­trac­tors will have the largest ca­pac­i­ty vol­ume. Those four are Ko­rea’s Sam­sung Bi­o­log­ics, Switzer­land’s Lon­za, WuXi Bi­o­log­ics, and Fu­ji­film Diosynth Biotech­nolo­gies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER